Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5 VLP influenza vaccine + GLA-SE
- Development stage
- Unknown
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
A plant-derived combination vaccine containing **H5 virus-like particles (VLPs)** displaying the hemagglutinin (HA) protein from the A/Indonesia/05/2005 H5N1 influenza strain, formulated with the adjuvant **GLA-SE** (glucopyranosyl lipid adjuvant-stable emulsion). The vaccine is designed to induce both humoral (HI titers) and cell-mediated immune responses, and has shown the ability to elicit robust, durable, and cross-reactive immune responses in adults. GLA-SE is a synthetic TLR4 agonist formulated in a nanoemulsion, promoting Th1-biased immunity and strong antibody responses. The product was tested in clinical trials as a pandemic and seasonal influenza vaccine candidate, demonstrating seroprotection and seroconversion rates suitable for regulatory licensure at low antigen doses[1][2][4].
- Other names
- H5 VLP + GLA-SEplant-derived H5VLP + GLA-SEH5 influenza VLP vaccine adjuvanted with GLA-SEH-5 influenza VLP vaccine adjuvanted with GLA-SEH 5 influenza VLP vaccine adjuvanted with GLA-SE
02
Targets
HA (Hemagglutinin)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on H5 VLP influenza vaccine + GLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5 VLP influenza vaccine + GLA-SE.